ATE283372T1 - Genvarianten des angiotensinogens und veranlagung zum bluthochdruck - Google Patents

Genvarianten des angiotensinogens und veranlagung zum bluthochdruck

Info

Publication number
ATE283372T1
ATE283372T1 AT94903230T AT94903230T ATE283372T1 AT E283372 T1 ATE283372 T1 AT E283372T1 AT 94903230 T AT94903230 T AT 94903230T AT 94903230 T AT94903230 T AT 94903230T AT E283372 T1 ATE283372 T1 AT E283372T1
Authority
AT
Austria
Prior art keywords
angiotensinogen
hypertension
presidention
genetic variants
association
Prior art date
Application number
AT94903230T
Other languages
English (en)
Inventor
Jean-Marc Lalouel
Xavier Jeunemaitre
Richard P Lifton
Florent Soubrier
Youri Kotelevtsev
Pierre Corvol
Original Assignee
Univ Utah Res Found
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Utah Res Found, Inst Nat Sante Rech Med filed Critical Univ Utah Res Found
Application granted granted Critical
Publication of ATE283372T1 publication Critical patent/ATE283372T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
AT94903230T 1992-09-30 1993-09-29 Genvarianten des angiotensinogens und veranlagung zum bluthochdruck ATE283372T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/952,442 US5374525A (en) 1992-09-30 1992-09-30 Methods to determine predisposition to hypertension and association of variant angiotensinogen gene and hypertension
PCT/US1993/009136 WO1994008048A1 (en) 1992-09-30 1993-09-29 Angiotensinogen gene variants and predisposition to hypertension

Publications (1)

Publication Number Publication Date
ATE283372T1 true ATE283372T1 (de) 2004-12-15

Family

ID=25492918

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94903230T ATE283372T1 (de) 1992-09-30 1993-09-29 Genvarianten des angiotensinogens und veranlagung zum bluthochdruck

Country Status (10)

Country Link
US (5) US5374525A (de)
EP (1) EP0665898B1 (de)
JP (1) JP3159708B2 (de)
KR (1) KR950704507A (de)
AT (1) ATE283372T1 (de)
AU (1) AU670990B2 (de)
CA (1) CA2145415A1 (de)
DE (1) DE69333710D1 (de)
NZ (1) NZ259092A (de)
WO (1) WO1994008048A1 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6153386A (en) * 1992-09-30 2000-11-28 University Of Utah Research Foundation Method to determine predisposition to hypertension
US5374525A (en) * 1992-09-30 1994-12-20 University Of Utah Research Foundation Methods to determine predisposition to hypertension and association of variant angiotensinogen gene and hypertension
US5750345A (en) * 1995-10-31 1998-05-12 Evanston Hospital Corporation Detection of human α-thalassemia mutations and their use as predictors of blood-related disorders
DE19613606C1 (de) 1996-04-04 1997-04-30 Progen Biotechnik Gmbh Gen für Hypertonie
US6114118A (en) * 1996-09-20 2000-09-05 Texas A&M University System Method of identification of animals resistant or susceptible to disease such as ruminant brucellosis, tuberculosis, paratuberculosis and salmonellosis
US6197505B1 (en) * 1997-04-04 2001-03-06 Pyrosequencing Ab Methods for assessing cardiovascular status and compositions for use thereof
US20020123467A1 (en) * 1999-09-02 2002-09-05 Institut Pasteur Therapeutic composition comprising the KAL protein and use of the KAL protein for the treatment of retinal, renal, neuronal and neural injury
US6194556B1 (en) * 1997-12-11 2001-02-27 Millennium Pharmaceuticals, Inc. Angiotensin converting enzyme homolog and therapeutic and diagnostic uses therfor
US6610497B1 (en) * 1997-12-11 2003-08-26 Millennium Pharmaceuticals, Inc. Angiotensin converting enzyme homolog and therapeutic and diagnostic uses therefor
US6893877B2 (en) 1998-01-12 2005-05-17 Massachusetts Institute Of Technology Methods for screening substances in a microwell array
WO1999034920A1 (en) * 1998-01-12 1999-07-15 Massachusetts Institute Of Technology Method and apparatus for performing microassays
US6525185B1 (en) 1998-05-07 2003-02-25 Affymetrix, Inc. Polymorphisms associated with hypertension
US6495338B1 (en) 1998-09-04 2002-12-17 University Of Utah Research Foundation Drug screening and diagnosis based on paracrine tubular renin-angiotensin system
DE69920032T2 (de) * 1998-11-10 2005-09-15 Genset Methoden, software und apparate zur identifizierung genomischer bereiche, die ein gen umfassen, das mit einem nachweisbaren merkmal assoziiert ist
US6306578B1 (en) * 1999-03-19 2001-10-23 Genencor International, Inc. Multi-through hole testing plate for high throughput screening
US6902888B1 (en) * 1999-05-21 2005-06-07 Myriad Genetics, Inc. Diabetes gene
AU5016200A (en) * 1999-05-21 2000-12-12 Myriad Genetics, Inc. Diabetes gene
US20020119448A1 (en) * 1999-06-23 2002-08-29 Joseph A. Sorge Methods of enriching for and identifying polymorphisms
US6177252B1 (en) * 1999-08-27 2001-01-23 University Of Utah Research Foundation Method to determine predisposition to hypertension
US7076437B1 (en) 1999-10-29 2006-07-11 Victor Levy Process for consumer-directed diagnostic and health care information
US20020151040A1 (en) 2000-02-18 2002-10-17 Matthew O' Keefe Apparatus and methods for parallel processing of microvolume liquid reactions
US7332271B2 (en) * 2000-02-18 2008-02-19 Board Of Trustees Of The Leland Stanford Junior University Apparatus and methods for parallel processing of micro-volume liquid reactions
AU2001264950A1 (en) * 2000-05-26 2001-12-11 Duke University Methods of screening for parkinson's disease
AU2001273661A1 (en) * 2000-06-30 2002-01-14 Duke University Methods of screening for alzheimer's disease
US20050239125A1 (en) * 2000-09-06 2005-10-27 Hodge Timothy A Methods for genotype screening
US20030219776A1 (en) * 2001-12-18 2003-11-27 Jean-Marc Lalouel Molecular variants, haplotypes and linkage disequilibrium within the human angiotensinogen gene
JP2006510341A (ja) * 2002-02-27 2006-03-30 バイエル・ヘルスケア・アクチェンゲゼルシャフト 有害薬剤反応および薬剤効力を予測する単一ヌクレオチド多型
US20040014109A1 (en) * 2002-05-23 2004-01-22 Pericak-Vance Margaret A. Methods and genes associated with screening assays for age at onset and common neurodegenerative diseases
US20060183117A1 (en) * 2002-07-08 2006-08-17 Pericak-Vance Margaret A Screening for alzheimer's disease
US8277753B2 (en) 2002-08-23 2012-10-02 Life Technologies Corporation Microfluidic transfer pin
EP1608952B1 (de) 2002-12-20 2016-08-10 Life Technologies Corporation Assay vorrichtung und verfahren unter verwendung von mikrofluiden matrixstrukturen
US20060246437A1 (en) * 2003-07-11 2006-11-02 Pericak-Vance Margaret A Genetic susceptibility genes for asthma and atopy and asthma-related and atopic-related phenotypes
US20060068428A1 (en) * 2003-11-03 2006-03-30 Duke University Identification of genetic markers associated with parkinson disease
US20050191652A1 (en) * 2003-11-03 2005-09-01 Vance Jeffery M. Identification of genetic forms of a gene that leads to high risk for parkinson disease
WO2005089945A1 (en) 2004-03-12 2005-09-29 Biotrove, Inc. Nanoliter array loading
US20060105453A1 (en) 2004-09-09 2006-05-18 Brenan Colin J Coating process for microfluidic sample arrays
US12070731B2 (en) 2004-08-04 2024-08-27 Life Technologies Corporation Methods and systems for aligning dispensing arrays with microfluidic sample arrays
US7807465B2 (en) * 2004-10-27 2010-10-05 Duke University Methods for identifying an individual at increased risk of developing coronary artery disease
US7790390B2 (en) * 2004-10-27 2010-09-07 Duke University Methods for identifying an individual at increased risk of developing coronary artery disease
WO2006069592A2 (en) * 2004-12-31 2006-07-06 Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg Method for diagnosing an/or predicting preeclampsia and/or related disorders
US20070148661A1 (en) * 2005-07-19 2007-06-28 Duke University LSAMP Gene Associated With Cardiovascular Disease
JP2007075015A (ja) * 2005-09-14 2007-03-29 Tokai Univ 高血圧症の検査用マーカー遺伝子
US20110044963A1 (en) * 2009-03-09 2011-02-24 Puschett Jules B Method of Testing a Patient for Hypertension and Related Method of Treatment and Test Kit
SG11201609376SA (en) 2014-05-22 2016-12-29 Alnylam Pharmaceuticals Inc Angiotensinogen (agt) irna compositions and methods of use thereof
CN108588211B (zh) * 2018-05-02 2020-05-19 青岛泱深生物医药有限公司 一种子痫前期的生物标志物及其应用
TWI851574B (zh) 2018-05-14 2024-08-11 美商阿尼拉製藥公司 血管收縮素原(AGT)iRNA組成物及其使用方法
IL292865A (en) 2019-11-13 2022-07-01 Alnylam Pharmaceuticals Inc Methods and preparations for the treatment of angiotensinogen-related disorder - (agt)
IL309296A (en) 2021-06-30 2024-02-01 Alnylam Pharmaceuticals Inc Methods and compositions for the treatment of angiotensinogen-related disorder (AGT-)
CA3228255A1 (en) 2021-08-04 2023-02-09 Alnylam Pharmaceuticals, Inc. Irna compositions and methods for silencing angiotensinogen (agt)
WO2025128614A1 (en) 2023-12-12 2025-06-19 Alnylam Pharmaceuticals, Inc. Methods and compositions for treating an angiotensinogen- (agt-) associated disorder
WO2026133251A1 (en) 2024-12-20 2026-06-25 Novartis Ag Combinations of antisense agents, pharmaceutical compositions and methods of use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5374525A (en) * 1992-09-30 1994-12-20 University Of Utah Research Foundation Methods to determine predisposition to hypertension and association of variant angiotensinogen gene and hypertension
US6153386A (en) * 1992-09-30 2000-11-28 University Of Utah Research Foundation Method to determine predisposition to hypertension

Also Published As

Publication number Publication date
US5589584A (en) 1996-12-31
US5374525A (en) 1994-12-20
AU670990B2 (en) 1996-08-08
AU5725094A (en) 1994-04-26
US5998145A (en) 1999-12-07
CA2145415A1 (en) 1994-04-14
US6165727A (en) 2000-12-26
EP0665898A4 (de) 1998-08-05
NZ259092A (en) 1996-05-28
JPH08505043A (ja) 1996-06-04
EP0665898A1 (de) 1995-08-09
KR950704507A (ko) 1995-11-20
US5763168A (en) 1998-06-09
WO1994008048A1 (en) 1994-04-14
JP3159708B2 (ja) 2001-04-23
EP0665898B1 (de) 2004-11-24
DE69333710D1 (de) 2004-12-30

Similar Documents

Publication Publication Date Title
DE69333710D1 (de) Genvarianten des angiotensinogens und veranlagung zum bluthochdruck
FI953812A7 (fi) Kohdistettujen geenien säädelty transkriptio ja muita biologisia toimintoja
ES2154252T1 (es) Inhibicion de la quinasa p38 utilizando difenil-ureas simetricas y asimetricas.
DE69729646D1 (de) Formulierung zur verwendung in der vorbeugung von pathogen-induzierten erkrankungen, einschliesslich hiv und hsv
ATE231187T1 (de) Methoden zur detektion von mikrometastasen bei prostata-krebs
DE3788691D1 (de) Verhütung von Fusariumkrankheiten und Mikroorganismen dafür.
ATE258437T1 (de) Chinolone und deren therapeutische verwendung
BG101835A (bg) Нови дипептидни амидини и използването им като инхибитори на тромбин
NO307513B1 (no) 2,8-disubstituert chinazolinon og anvendelse derav
DE69625769D1 (de) Verteiler zur unabhängigen Ein- und/oder Abführung von Fluiden
DE69627153D1 (de) Zusammensetzungen zur erzielung von analgesie und zur hemmung der progression neuropathischer schmerzerkrankungen
DE69534908D1 (de) Verwendung von statin zur behandlung von hauterkrankungen
DE69737044D1 (de) Herstellung von fugizides Chinazolinonen und nützliche Zwischenprodukte
DK0470136T3 (da) Terapeutisk middel
DE69320052D1 (de) Topoisomerase ii inhibitoren sowie deren therapeutische verwendung
BG101338A (en) Dna encoding human papillomavirus type 6a
DE19681439T1 (de) Modifizierung von Polypeptidarzneimitteln zur Erhöhung des Elektrotransportflusses
DE69702554D1 (de) Aminopeptidase GX und damit Hydrolysierungsverfahren von Proteine
DE69630391D1 (de) Prolylendopeptidase-inhibitoren, ihre herstellung und ihre pharmazeutische verwendung
EP1914312A3 (de) Virulenzgene und -proteine sowie ihre Anwendung
IT8622548A0 (it) Procedimento d'epurazione e di deodorizzazione di gas e installazione per la messa in opera di questo procedimento.
DE3686019D1 (de) Die verwendung von nitrofurantoin zur behandlung und verhuetung von magen-darmkrankheiten.
DE69618657D1 (de) Visuelle und/oder akustische hilfe zum persönlichen gebrauch, sowie gebrauch dieser hilfe
ATE348154T1 (de) Transkriptionsfaktor e2f-5
FR2710539B1 (fr) Ensemble d'aiguille chirurgicale.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties